• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Impact of age on long-term anticoagulation and how gender and monitoring setting affect it: implications for decision making and patient management.年龄对长期抗凝治疗的影响以及性别和监测环境如何对其产生影响:对决策制定和患者管理的启示
Br J Clin Pharmacol. 2016 Oct;82(4):1076-83. doi: 10.1111/bcp.13046. Epub 2016 Jul 24.
2
Anticoagulation control and cost of monitoring of older patients on chronic warfarin therapy in three settings in North East England.英格兰东北部三个地区接受慢性华法林治疗的老年患者的抗凝控制及监测成本
Age Ageing. 2014 Sep;43(5):708-11. doi: 10.1093/ageing/afu074. Epub 2014 Jun 18.
3
Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.基于国际标准化比值自我检测、在线远程监测与管理以及低剂量维生素K并考虑基因组因素的华法林管理评估:一项试点研究。
Pharmacotherapy. 2013 Nov;33(11):1136-46. doi: 10.1002/phar.1343. Epub 2013 Aug 22.
4
Individual and monitoring centre influences upon anticoagulation control of AF patients on warfarin: A longitudinal multi-centre UK-based study.个体和监测中心对服用华法林的房颤患者抗凝控制的影响:一项基于英国的纵向多中心研究。
Eur J Haematol. 2018 Oct;101(4):486-495. doi: 10.1111/ejh.13130. Epub 2018 Aug 3.
5
6
Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.止血专家对接受维生素K拮抗剂治疗的心房颤动患者的慢性抗凝控制质量及在治疗范围内的时间进行评估:TERRA注册研究:阿根廷共和国的目标时间范围。
Clin Appl Thromb Hemost. 2017 Jul;23(5):445-453. doi: 10.1177/1076029615623378. Epub 2016 Jan 5.
7
Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation.心房颤动患者抗凝治疗的教育与行为干预措施
Cochrane Database Syst Rev. 2013 Jun 4(6):CD008600. doi: 10.1002/14651858.CD008600.pub2.
8
Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry.评估华法林在治疗范围内的时间对土耳其心房颤动患者结局的影响:来自观察性前瞻性WATER注册研究的观点
Cardiol J. 2015;22(5):567-75. doi: 10.5603/CJ.a2015.0035. Epub 2015 Jun 23.
9
Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.影响心房颤动抗凝控制质量和血管事件的遗传与非遗传因素
J Stroke Cerebrovasc Dis. 2017 Jun;26(6):1383-1390. doi: 10.1016/j.jstrokecerebrovasdis.2017.02.022. Epub 2017 Apr 12.
10
Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.预测房颤患者在住院环境中使用华法林的因素。
Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.

引用本文的文献

1
Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets and drug metabolism genes.性别偏向的药物作用靶点和药物代谢基因的性别偏向表达和基因调控网络。
BMC Pharmacol Toxicol. 2024 Jan 2;25(1):5. doi: 10.1186/s40360-023-00727-1.
2
Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets and drug metabolism genes.性别偏向性基因表达以及性别偏向性不良事件药物靶点和药物代谢基因的基因调控网络。
bioRxiv. 2023 Nov 15:2023.05.23.541950. doi: 10.1101/2023.05.23.541950.
3
Sex Differences in Oral Anticoagulation Therapy in Patients Hospitalized With Atrial Fibrillation: A Nationwide Cohort Study.口服抗凝治疗与住院心房颤动患者的性别差异:一项全国性队列研究。
J Am Heart Assoc. 2023 Mar 7;12(5):e027211. doi: 10.1161/JAHA.122.027211. Epub 2023 Mar 2.
4
Low Quality of Warfarin Therapy is Associated With Female Gender but Not With Polypharmacy in Patients With Atrial Fibrillation.华法林治疗质量低下与房颤患者的女性性别相关,但与多药联用无关。
Front Pharmacol. 2021 Apr 26;12:651799. doi: 10.3389/fphar.2021.651799. eCollection 2021.
5
Health-related quality of life in nonvalvular atrial fibrillation patients with controlled or uncontrolled anticoagulation status.非瓣膜性心房颤动患者抗凝控制或未控制状态下的健康相关生活质量。
Health Qual Life Outcomes. 2020 Dec 11;18(1):383. doi: 10.1186/s12955-020-01563-1.
6
Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K Antagonists in Spain. A population-based, real-world study.西班牙华法林抗凝治疗的房颤患者中,女性与男性在 INR 控制和转为非维生素 K 口服抗凝剂方面的差异:一项基于人群的真实世界研究。
PLoS One. 2019 Feb 12;14(2):e0211681. doi: 10.1371/journal.pone.0211681. eCollection 2019.

本文引用的文献

1
Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression.维生素 K 拮抗剂控制质量与心房颤动患者结局的关系:一项荟萃分析和荟萃回归。
Thromb J. 2014 Jun 24;12:14. doi: 10.1186/1477-9560-12-14. eCollection 2014.
2
Anticoagulation control and cost of monitoring of older patients on chronic warfarin therapy in three settings in North East England.英格兰东北部三个地区接受慢性华法林治疗的老年患者的抗凝控制及监测成本
Age Ageing. 2014 Sep;43(5):708-11. doi: 10.1093/ageing/afu074. Epub 2014 Jun 18.
3
Pathways to poor anticoagulation control.导致抗凝控制不佳的因素。
J Thromb Haemost. 2014 May;12(5):628-34. doi: 10.1111/jth.12530.
4
Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials.华法林处于治疗范围时间对卒中及大出血发生率的影响评估及其对与新型口服抗凝药使用相关的医疗费用节省的影响——来自ARISTOTLE、ROCKET-AF及RE-LY试验的经验教训
J Thromb Thrombolysis. 2014;38(2):150-9. doi: 10.1007/s11239-013-1048-z.
5
The quality of oral anticoagulation in general practice in patients with atrial fibrillation.心房颤动患者在全科医疗中的口服抗凝治疗质量。
Eur J Intern Med. 2014 Mar;25(3):247-54. doi: 10.1016/j.ejim.2013.12.013. Epub 2014 Jan 27.
6
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.新型口服抗凝剂与华法林治疗心房颤动患者的疗效和安全性比较:随机试验的荟萃分析。
Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.
7
Use of vitamin K antagonist therapy in geriatrics: a French national survey from the French Society of Geriatrics and Gerontology (SFGG).老年患者使用维生素 K 拮抗剂治疗的情况:来自法国老年医学和老年学学会(SFGG)的一项法国全国性调查。
Drugs Aging. 2013 Dec;30(12):1019-28. doi: 10.1007/s40266-013-0127-3.
8
Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF).2010 年 ESC 心房颤动指南发布后七个欧洲国家的心房颤动管理:预防血栓栓塞事件-心房颤动欧洲登记研究(PREFER in AF)的初步结果。
Europace. 2014 Jan;16(1):6-14. doi: 10.1093/europace/eut263. Epub 2013 Oct 1.
9
Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry.新诊断为有卒中风险的房颤患者的风险概况和抗血栓治疗:来自国际、观察性、前瞻性 GARFIELD 注册研究的观点。
PLoS One. 2013 May 21;8(5):e63479. doi: 10.1371/journal.pone.0063479. Print 2013.
10
Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score.华法林抗凝治疗的心房颤动患者抗凝控制质量的影响因素:SAMe-TT₂R₂评分。
Chest. 2013 Nov;144(5):1555-1563. doi: 10.1378/chest.13-0054.

年龄对长期抗凝治疗的影响以及性别和监测环境如何对其产生影响:对决策制定和患者管理的启示

Impact of age on long-term anticoagulation and how gender and monitoring setting affect it: implications for decision making and patient management.

作者信息

Abohelaika Salah, Wynne Hilary, Avery Peter, Robinson Brian, Kesteven Patrick, Kamali Farhad

机构信息

Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.

Older People's Medicine, Newcastle upon Tyne Hospitals, NHS Foundation Trust, UK.

出版信息

Br J Clin Pharmacol. 2016 Oct;82(4):1076-83. doi: 10.1111/bcp.13046. Epub 2016 Jul 24.

DOI:10.1111/bcp.13046
PMID:27314636
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5137833/
Abstract

AIMS

Stabilization of anticoagulation control is seminal to reducing the risk of adverse effects of vitamin K antagonists. Reliable information on how ageing influences this is lacking. We set out to assess the true age-related changes in anticoagulation control, how gender and patient setting influence this, and the possible implications of these for patient outcomes and management.

METHODS

In atrial fibrillation (AF) patients of a unified anticoagulant service monitoring patients in general practice or hospital-based clinics and housebound patients at home, international normalized ratio (INR) and warfarin dose data between 2000 and 2013 were extracted via the DAWN dosing program. Anticoagulation control was assessed by calculating percentage time spent within target INR (TTR).

RESULTS

A total of 2094 AF patients [938 (44.8%) in general practice (GP) and 531 (25.4%) in hospital (H)-based clinics and 625 (29.8%) through the domiciliary service (D)] were evaluated. The frequency of warfarin dose changes and INR monitoring events declined until about age 67, then increased as patients got older. The TTR according to age was significantly lower and the probability of having a TTR ≤65% according to age was higher for D than for H and GP, and females had a greater probability of having a TTR ≤65% than age-matched males.

CONCLUSION

Identification of factors underlying poorer anticoagulation control in older housebound patients and the introduction of effective modifications to improve the clinical effectiveness of anticoagulation in such patients is needed.

摘要

目的

稳定抗凝控制对于降低维生素K拮抗剂不良反应风险至关重要。目前缺乏关于衰老如何影响这一过程的可靠信息。我们旨在评估抗凝控制中与年龄相关的真实变化、性别和患者情况如何影响这一变化,以及这些变化对患者预后和管理的可能影响。

方法

通过DAWN给药程序提取2000年至2013年期间在综合实践或医院门诊接受统一抗凝服务监测的房颤(AF)患者以及居家患者的国际标准化比值(INR)和华法林剂量数据。通过计算处于目标INR(TTR)范围内的时间百分比来评估抗凝控制情况。

结果

共评估了2094例房颤患者[938例(44.8%)在综合实践(GP)中,531例(25.4%)在医院(H)门诊,625例(29.8%)通过居家服务(D)]。华法林剂量变化频率和INR监测事件在67岁左右之前下降,然后随着患者年龄增长而增加。根据年龄,居家服务组的TTR显著更低,且根据年龄TTR≤65%的概率高于医院门诊组和综合实践组,女性TTR≤65%的概率高于年龄匹配的男性。

结论

需要确定居家老年患者抗凝控制较差的潜在因素,并进行有效调整以提高此类患者抗凝治疗的临床效果。